In this presentation, Dr Mike Hubank, Scientific Director of the North Thames GLH provides an overview of the clinical testing and reporting pathways associated with managing cancer patients with NTRK gene-fusions.
Recorded in June 2021 as part of The Genomic Medicine Service and NTRK Tumour Agnostic Testing and Treatment Pathways in Solid Tumours virtual meeting. You can view the other presentations from the meeting by following the links below;
- The role of the Genomic Medicine Service in precision oncology. Dr Angela George, Clinical Director (Cancer) of the North Thames GLH
- Genomic testing in cancer: NTRK Sample requirements, tumour assessments and optimising tissue pathways. Professor Louise Jones, Pathology Lead, North Thames GLH
- The NTRK testing and treatment landscape and patient case study: A clinician’s perspective Dr Martin Forster, Associate Professor and Consultant in Medical Oncology UCL Cancer Institute. This presentation was sponsored by Bayer and the video is hosted on a Bayer promotional website. To leave the North Thames GLH website and access this presentation on the Bayer website, please click here